Respiratory distress syndrome (RDS) is a breathing disorder that affects newborns. RDS rarely occurs in full-term infants. The disorder is more common in premature infants born about 6 weeks or ...

Certain factors may increase the risk that your infant will develop respiratory distress syndrome RDS Read to know more!

Discovery Laboratories announced that the FDA has approved Surfaxin (lucinactant intratracheal suspension) for prevention of respiratory distress syndrome (RDS) in high-risk premature infants.

Preterm infants with respiratory distress syndrome (RDS) face heightened risks of death, critical illness, and prolonged hospitalization, particularly if they progress to develop acute respiratory ...

The study is the first to identify a single gene -- ABCA3 -- that is associated with a significant number of cases of respiratory distress syndrome (RDS) in babies born at or near full term.

To determine if histologic chorioamnionitis (HC) in the presence of respiratory distress syndrome (RDS) augments adverse pulmonary outcomes in extremely low birth weight (ELBW) infants. We ...

Discovery Laboratories announced its launch of Surfaxin (lucinactant) Intratracheal Suspension for the prevention of respiratory distress syndrome (RDS) in premature infants at high-risk for RDS.

Respiratory distress syndrome (RDS) is the predominant clinical problem encountered in neonatal units. Incidence increases with lower gestational age.

Surfactant therapy prevents the development of respiratory distress syndrome (RDS) in many premature infants and shortens the course of RDS in others. 1, 2, 3 Although universal (prophylactic ...

Neonatal respiratory distress syndrome (RDS) is a breathing problem linked with underdeveloped lungs and lack of surfactant, a slippery, protective coating in the inside of the lungs that helps to ...

Premature babies do not have fully formed lungs, and they are at risk of developing a breathing disease called Respiratory Distress Syndrome (RDS). Without proper care, about half of all babies ...